Up-to-$1.2B Neurodegenerative Disease Collaboration Launched by Takeda, Denali

Takeda Pharmaceutical and Denali Therapeutics said today they will partner to develop up to three therapeutic candidates for neurodegenerative diseases, including Alzheimer’s disease, through a collaboration that could generate about $1.2 billion for Denali.Takeda plans to use Denali’s Antibody Transport Vehicle ™ (ATV) platform for increased exposure of biotherapeutic products, a technology designed to enhance penetration of the blood–brain barrier. Each treatment would